Stockscreener 앱 받기
9.45
0.43%
0.04
Poseida Therapeutics Inc 주식(PSTX)의 최신 뉴스
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Poseida Therapeutics, Inc. (NASDAQ:PSTX) Stock Position Lowered by Wellington Management Group LLP - MarketBeat
Poseida Therapeutics (NASDAQ:PSTX) Sets New 52-Week HighHere's What Happened - MarketBeat
XTX Topco Ltd Increases Stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX) - MarketBeat
Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Poseida Therapeutics executive chairman sells $283,866 in stock By Investing.com - Investing.com Canada
Poseida Therapeutics executive chairman sells $283,866 in stock - Investing.com
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 - The Eastern Progress Online
Poseida Therapeutics to Present at Two Upcoming Investor Conferences - The Eastern Progress Online
Poseida Therapeutics' SWOT analysis: gene therapy firm's stock shows promise amid challenges - Investing.com Nigeria
Poseida Therapeutics' SWOT analysis: gene therapy firm's stock shows promise amid challenges By Investing.com - Investing.com South Africa
Roche initially didn't want to buy Poseida — and partner Astellas didn't submit an offer, new filings show - Endpoints News
Poseida Therapeutics (NASDAQ:PSTX) Reaches New 1-Year HighStill a Buy? - MarketBeat
Poseida reports positive interim data on CAR-T therapies By Investing.com - Investing.com Canada
Roche: launch of takeover bid for Poseida Therapeutics - Marketscreener.com
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash - The Manila Times
Roche commences tender offer for outstanding Poseida shares at $9 per share - TipRanks
Roche Launches $9/Share Cash Tender Offer for Poseida Therapeutics, CVR Could Add $4 More - StockTitan
Roche commences tender offer for all shares of Poseida - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PSTX, CCRN, PLL on Behalf of Shareholders - Marketscreener.com
Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting - BioSpace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Poseida reports positive interim data on CAR-T therapies - Investing.com
Jacobs Levy Equity Management Inc. Sells 115,494 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) - MarketBeat
Poseida Therapeutics to Present at Upcoming Investor Conferences - Longview News-Journal
PBF Energy, Poseida Therapeutics, and More Stocks See Action From Activist Investors - MSN
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting - The Eastern Progress Online
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Poseida Therapeutics, Inc.PSTX - The Eastern Progress Online
Poseida Therapeutics (STU:2RZ) GF Value Rank : 1 (As of Dec. 04, 2024) - GuruFocus.com
Poseida Therapeutics stock soars to 52-week high of $9.43 By Investing.com - Investing.com Canada
Poseida Therapeutics stock soars to 52-week high of $9.43 - Investing.com
Roche to buy Poseida, building on CAR-T cell collaboration - Multiple Sclerosis News Today
Roche Agrees To Acquire Poseida Therapeutics - Contract Pharma
Roche Acquires Poseida for $1.5B - San Diego Business Journal
Big Pharma, big CGT deals: Roche buying Poseida, Novartis buys Kate - BioProcess Insider
Fred Alger Management LLC Buys Shares of 128,970 Poseida Therapeutics, Inc. (NASDAQ:PSTX) - MarketBeat
The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis - Yahoo Finance
Poseida Therapeutics Stock Hits Over 3-Year Highs On Roche’s $1.5B Buyout Deal: Retail Is Euphoric - MSN
Roche to acquire Poseida Therapeutics for USD 1.5 billion - Medical Dialogues
Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success - MSN
Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet - MSN
Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross? - MSN
Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue? - MSN
Poseida Therapeutics (FRA:2RZ) Degree of Operating Leverage : -0.28 (As of Sep. 2024) - GuruFocus.com
Bold Move by Roche: Pioneering the Future of Cell Therapy - substack.com
2.88%
2.65%
자본화:
|
볼륨(24시간):